EXPERIMENTAL ANTI-ANGIOGENIC THERAPY FOR UTERINE SARCOMA
| Project/Area Number |
11671664
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | FUKUOKA UNIVERSITY |
|---|
Principal Investigator |
HONJO Ko (2000) School of Medicine, FUKUOKA UNIVERSITY, Assistant Professor, 医学部, 助手 (20299564)
江本 精 (1999) 福岡大学, 医学部, 講師 (80258540)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
EMOTO Makoto School of Medicine, FUKUOKA UNIVERSITY, Lecturer, 医学部, 講師 (80258540)
OHSHIMA Koichi Sch.Medicine, FUKUOKA UNIVERSITY, Associate Professor, 医学部, 助教授 (50203766)
本庄 考 福岡大学, 医学部, 助手 (20299564)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2000: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | UTERINE SARCOMA / CARCINOSARCOMA / ANGIOGENESIS / ANTI-ANGIOGENIC THERAPY / TISSUE CULTURE / VASCULAR ENDOTHELIAL GROWTH FACTOR / MTT ASSAY / TNP-470 / VEGF / 子宮 / 超音波カラードプラ / 微小血管密度 |
|---|
| Research Abstract |
Uterine sarcoma is the most aggressive neoplasm among the known uterine malignancies. This is the first study to examine the inhibitory and anti-angiogenic effects of angiogenesis inhibitor TNP-470, a synthetic analogue of fumagillin, for human uterine carcinosarcoma in vitro and in vivo. The direct growth-inhibitory effect of TNP-470 was examined by an MTT assay in vitro. The levels of vascular endothelial growth factor (VEGF) in the culture supernate of TNP-470 treated FU-MMT-1 cells were also analyzed by an ELISA.The VEGF expression of TNP-470 treated FU-MMT-1 cells was also immunohistochemically examined using an anti-VEGF antibody. TNP-470 (30 mg/ kg, three times per week during five weeks' periods) were examined after inoculating of a human uterine carcinosarcoma cell line, FU-MMT-1, in nude mice. TNP-470 inhibited the growth of FU-MMT-1 cells in vitro. The level of VEGF in the culture supernatant of TNP-470 treated FU-MMT-1 cells was significantly lower than that of the control in vitro. TNP-470 significantly reduced the volume as well as the weight of the xenografts when this therapy was started the three weeks after the inoculation of FU-MMT-1, in comparison to the controls. Our findings suggest that this angiogenesis inhibitor, TNP-470, might be a novel therapeutic agent for uterine sarcoma.
|
Report
(3 results)
Research Products
(4 results)
